Karen Hagerty
Overview
Explore the profile of Karen Hagerty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
781
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bourbeau B, Hagerty K, Dickson N, Polite B, Chasky M, Grubbs S
JCO Oncol Pract
. 2022 Oct;
18(11):737-741.
PMID: 36252157
No abstract available.
2.
Pennell N, Dillmon M, Levit L, Moushey E, Alva A, Blau S, et al.
J Clin Oncol
. 2020 Dec;
39(2):155-169.
PMID: 33290128
This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and...
3.
Hagerty K
J Oncol Pract
. 2018 Feb;
6(3):157-158.
PMID: 29436948
The FDA recently announced an oncology-specific Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents prescribed under approved indications: The APPRISE program.
4.
Hanley A, Hagerty K, Towle E, Neuss M, Mulvey T, Acheson A
J Oncol Pract
. 2014 Mar;
10(2):143-8.
PMID: 24633290
Purpose: The American Society of Clinical Oncology (ASCO) National Oncology Census (Census) provides a mechanism for ASCO to systematically gather and analyze information about current practice structures and potential changes...
5.
Forte G, Hanley A, Hagerty K, Kurup A, Neuss M, Mulvey T
J Oncol Pract
. 2013 May;
9(1):9-19.
PMID: 23633966
In response to reports of increasing financial and administrative burdens on oncology practices and a lack of systematic information related to these issues, American Society of Clinical Oncology (ASCO) leadership...
6.
Link M, Hagerty K, Kantarjian H
J Clin Oncol
. 2012 Feb;
30(7):692-4.
PMID: 22291078
No abstract available.
7.
Wilt T, MacDonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield M, et al.
BJU Int
. 2010 Oct;
106(10):1444-51.
PMID: 20977593
Objective: • To estimate the benefits and harms of 5-α-reductase inhibitors (5-α-RIs) in preventing prostate cancer. Materials And Methods: • We searched MEDLINE and the Cochrane Collaboration Library through June...
8.
Hagerty K
J Oncol Pract
. 2010 Sep;
4(6):267-70.
PMID: 20856755
The FDA sent a "Complete Response and Safety Labeling Change Order" to the sponsors of ESAs on July 30, ordering changes to ESA labels in three important ways. For the...
9.
Visvanathan K, Chlebowski R, Hurley P, Col N, Ropka M, Collyar D, et al.
J Clin Oncol
. 2009 May;
27(19):3235-58.
PMID: 19470930
PURPOSE To update the 2002 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. METHODS A literature search identified relevant randomized trials published since...
10.
Lee S, Schover L, Partridge A, Patrizio P, Wallace W, Hagerty K, et al.
J Clin Oncol
. 2006 May;
24(18):2917-31.
PMID: 16651642
Purpose: To develop guidance to practicing oncologists about available fertility preservation methods and related issues in people treated for cancer. Methods: An expert panel and a writing committee were formed....